Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.

Abstract

e11516 Background: The majority of patients presenting with hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-) advanced breast cancer (aBC) ultimately experience progression after 1st-line therapy. This study describes the characteristics, treatment patterns and outcomes of de novo aBC patients following progression on 1st-line therapy. Methods: Medical charts were reviewed for woman with HR+/HER2- de novo aBC treated in a community oncology network. Included patients had a 1st progression (index progression) between 1/1/2004 and 9/30/2010 after initiating 1st-line aBC treatment and no prior adjuvant treatment for aBC. The study was approved by the jurisdictional Institutional Review Board. Information was collected on patient demographics, metastases, treatment types and durations, and death. Kaplan-Meier analysis was used to estimate overall survival. Results: We studied 112 patients with de novo aBC who experienced progression on 1st-line treatment. At the time of ...